Difference between revisions of "Chronic myeloid leukemia - historical"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "https://www.nature.com/articles/24" to "https://doi.org/10.1038/sj.leu.24") |
m |
||
Line 1: | Line 1: | ||
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the [http://www.nccn.org/professionals/physician_gls/f_guidelines.asp NCCN Guidelines]. Is there a regimen missing from this list? See the [[Chronic myeloid leukemia|main CML page]] for current regimens. | The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the [http://www.nccn.org/professionals/physician_gls/f_guidelines.asp NCCN Guidelines]. Is there a regimen missing from this list? See the [[Chronic myeloid leukemia|main CML page]] for current regimens. | ||
− | |||
{| class="wikitable" style="float:right; margin-right: 5px;" | {| class="wikitable" style="float:right; margin-right: 5px;" | ||
|- | |- | ||
Line 6: | Line 5: | ||
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div> | <div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div> | ||
|} | |} | ||
− | |||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
− | |||
=Chronic phase, first-line therapy= | =Chronic phase, first-line therapy= | ||
==Hydroxyurea & Interferon alfa-2a {{#subobject:917a16|Regimen=1}}== | ==Hydroxyurea & Interferon alfa-2a {{#subobject:917a16|Regimen=1}}== | ||
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
− | |||
===Regimen {{#subobject:909575|Variant=1}}=== | ===Regimen {{#subobject:909575|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 100%; text-align:center;" | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
Line 33: | Line 29: | ||
| style="background-color:#91cf60" |Seems to have superior OS | | style="background-color:#91cf60" |Seems to have superior OS | ||
|- | |- | ||
− | |[https://www. | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4777774/ Gratwohl et al. 2015 (CML-Study IIIA)] |
|1997-2004 | |1997-2004 | ||
|style="background-color:#1a9851"|Phase 3 (C) | |style="background-color:#1a9851"|Phase 3 (C) | ||
Line 40: | Line 36: | ||
|- | |- | ||
|} | |} | ||
− | ''One of the few regimens compared in large RCTs against allogeneic HSCT.'' | + | ''Note: One of the few regimens compared in large RCTs against allogeneic HSCT.'' |
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Hydroxyurea (Hydrea)]] | *[[Hydroxyurea (Hydrea)]] | ||
====Immunotherapy==== | ====Immunotherapy==== | ||
*[[Interferon alfa-2a (Roferon-A)]] | *[[Interferon alfa-2a (Roferon-A)]] | ||
− | + | </div></div> | |
===References=== | ===References=== | ||
# '''CML-Study II:''' Hehlmann R, Berger U, Pfirrmann M, Hochhaus A, Metzgeroth G, Maywald O, Hasford J, Reiter A, Hossfeld DK, Kolb HJ, Löffler H, Pralle H, Queisser W, Griesshammer M, Nerl C, Kuse R, Tobler A, Eimermacher H, Tichelli A, Aul C, Wilhelm M, Fischer JT, Perker M, Scheid C, Schenk M, Weiss J, Meier CR, Kremers S, Labedzki L, Schmeiser T, Lohrmann HP, Heimpel H; German CML Study Group. Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea. Leukemia. 2003 Aug;17(8):1529-37. [https://doi.org/10.1038/sj.leu.2403006 link to original article] [https://pubmed.ncbi.nlm.nih.gov/12886239 PubMed] | # '''CML-Study II:''' Hehlmann R, Berger U, Pfirrmann M, Hochhaus A, Metzgeroth G, Maywald O, Hasford J, Reiter A, Hossfeld DK, Kolb HJ, Löffler H, Pralle H, Queisser W, Griesshammer M, Nerl C, Kuse R, Tobler A, Eimermacher H, Tichelli A, Aul C, Wilhelm M, Fischer JT, Perker M, Scheid C, Schenk M, Weiss J, Meier CR, Kremers S, Labedzki L, Schmeiser T, Lohrmann HP, Heimpel H; German CML Study Group. Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea. Leukemia. 2003 Aug;17(8):1529-37. [https://doi.org/10.1038/sj.leu.2403006 link to original article] [https://pubmed.ncbi.nlm.nih.gov/12886239 PubMed] | ||
# '''CML-Study III:''' Hehlmann R, Berger U, Pfirrmann M, Heimpel H, Hochhaus A, Hasford J, Kolb HJ, Lahaye T, Maywald O, Reiter A, Hossfeld DK, Huber C, Löffler H, Pralle H, Queisser W, Tobler A, Nerl C, Solenthaler M, Goebeler ME, Griesshammer M, Fischer T, Kremers S, Eimermacher H, Pfreundschuh M, Hirschmann WD, Lechner K, Wassmann B, Falge C, Kirchner HH, Gratwohl A. Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood. 2007 Jun 1;109(11):4686-92. Epub 2007 Feb 22. [http://www.bloodjournal.org/content/109/11/4686.long link to original article] '''does not contain dosing details''' [https://pubmed.ncbi.nlm.nih.gov/17317858 PubMed] NCT00002771 | # '''CML-Study III:''' Hehlmann R, Berger U, Pfirrmann M, Heimpel H, Hochhaus A, Hasford J, Kolb HJ, Lahaye T, Maywald O, Reiter A, Hossfeld DK, Huber C, Löffler H, Pralle H, Queisser W, Tobler A, Nerl C, Solenthaler M, Goebeler ME, Griesshammer M, Fischer T, Kremers S, Eimermacher H, Pfreundschuh M, Hirschmann WD, Lechner K, Wassmann B, Falge C, Kirchner HH, Gratwohl A. Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood. 2007 Jun 1;109(11):4686-92. Epub 2007 Feb 22. [http://www.bloodjournal.org/content/109/11/4686.long link to original article] '''does not contain dosing details''' [https://pubmed.ncbi.nlm.nih.gov/17317858 PubMed] NCT00002771 | ||
− | # '''CML-Study IIIA:''' Gratwohl A, Pfirrmann M, Zander A, Kröger N, Beelen D, Novotny J, Nerl C, Scheid C, Spiekermann K, Mayer J, Sayer HG, Falge C, Bunjes D, Döhner H, Ganser A, Schmidt-Wolf I, Schwerdtfeger R, Baurmann H, Kuse R, Schmitz N, Wehmeier A, Fischer JT, Ho AD, Wilhelm M, Goebeler ME, Lindemann HW, Bormann M, Hertenstein B, Schlimok G, Baerlocher GM, Aul C, Pfreundschuh M, Fabian M, Staib P, Edinger M, Schatz M, Fauser A, Arnold R, Kindler T, Wulf G, Rosselet A, Hellmann A, Schäfer E, Prümmer O, Schenk M, Hasford J, Heimpel H, Hossfeld DK, Kolb HJ, Büsche G, Haferlach C, Schnittger S, Müller MC, Reiter A, Berger U, Saußele S, Hochhaus A, Hehlmann R; SAKK; German CML Study Group. Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment. Leukemia. 2016 Mar;30(3):562-9. Epub 2015 Oct 14. [https://www.nature.com/articles/leu2015281 link to original article] '''does not contain dosing details''' [https://pubmed.ncbi.nlm.nih.gov/26464170 PubMed] NCT00025402 | + | # '''CML-Study IIIA:''' Gratwohl A, Pfirrmann M, Zander A, Kröger N, Beelen D, Novotny J, Nerl C, Scheid C, Spiekermann K, Mayer J, Sayer HG, Falge C, Bunjes D, Döhner H, Ganser A, Schmidt-Wolf I, Schwerdtfeger R, Baurmann H, Kuse R, Schmitz N, Wehmeier A, Fischer JT, Ho AD, Wilhelm M, Goebeler ME, Lindemann HW, Bormann M, Hertenstein B, Schlimok G, Baerlocher GM, Aul C, Pfreundschuh M, Fabian M, Staib P, Edinger M, Schatz M, Fauser A, Arnold R, Kindler T, Wulf G, Rosselet A, Hellmann A, Schäfer E, Prümmer O, Schenk M, Hasford J, Heimpel H, Hossfeld DK, Kolb HJ, Büsche G, Haferlach C, Schnittger S, Müller MC, Reiter A, Berger U, Saußele S, Hochhaus A, Hehlmann R; SAKK; German CML Study Group. Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment. Leukemia. 2016 Mar;30(3):562-9. Epub 2015 Oct 14. [https://www.nature.com/articles/leu2015281 link to original article] '''does not contain dosing details''' [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4777774/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/26464170 PubMed] NCT00025402 |
− | |||
==Interferon alfa monotherapy {{#subobject:7d153e|Regimen=1}}== | ==Interferon alfa monotherapy {{#subobject:7d153e|Regimen=1}}== | ||
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
===Regimen {{#subobject:8dab8f|Variant=1}}=== | ===Regimen {{#subobject:8dab8f|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 100%; text-align:center;" | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
Line 71: | Line 67: | ||
|- | |- | ||
|} | |} | ||
− | ''This article does not specify the exact type of interferon alfa.'' | + | ''Note: This article does not specify the exact type of interferon alfa.'' |
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Immunotherapy==== | ====Immunotherapy==== | ||
*[[:Category:Interferons|Interferon alfa]] | *[[:Category:Interferons|Interferon alfa]] | ||
− | |||
'''Continued indefinitely''' | '''Continued indefinitely''' | ||
+ | </div></div> | ||
===References=== | ===References=== | ||
# Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, Queisser W, Löffler H, Hochhaus A, Heinze B, Georgii A, Bartram CR, Griesshammer M, Bergmann L, Essers U, Falge C, Queisser U, Meyer P, Schmitz N, Eimermacher H, Walther F, Fett W, Kleeberg UR, Kabisch A, Nerl C, Zimmermann R, Meuret G, Tichelli A, Kanz L, Tigges FJ, Schmid L, Brockhaus W, Tobler A, Reiter A, Perker M, Emmerich B, Verpoort K, Zankovich R, Wussow PV, Prummer O, Thiele J, Buhr T, Carbonell F, Ansari H; German CML Study Group. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood. 1994 Dec 15;84(12):4064-77. [http://www.bloodjournal.org/content/84/12/4064.long link to original article] [https://pubmed.ncbi.nlm.nih.gov/7994025 PubMed] | # Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, Queisser W, Löffler H, Hochhaus A, Heinze B, Georgii A, Bartram CR, Griesshammer M, Bergmann L, Essers U, Falge C, Queisser U, Meyer P, Schmitz N, Eimermacher H, Walther F, Fett W, Kleeberg UR, Kabisch A, Nerl C, Zimmermann R, Meuret G, Tichelli A, Kanz L, Tigges FJ, Schmid L, Brockhaus W, Tobler A, Reiter A, Perker M, Emmerich B, Verpoort K, Zankovich R, Wussow PV, Prummer O, Thiele J, Buhr T, Carbonell F, Ansari H; German CML Study Group. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood. 1994 Dec 15;84(12):4064-77. [http://www.bloodjournal.org/content/84/12/4064.long link to original article] [https://pubmed.ncbi.nlm.nih.gov/7994025 PubMed] | ||
− | |||
=Chronic phase, relapsed or refractory= | =Chronic phase, relapsed or refractory= | ||
− | |||
==Busulfan monotherapy {{#subobject:24be30|Regimen=1}}== | ==Busulfan monotherapy {{#subobject:24be30|Regimen=1}}== | ||
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
===Regimen {{#subobject:b774ed|Variant=1}}=== | ===Regimen {{#subobject:b774ed|Variant=1}}=== | ||
{| class="wikitable" style="width: 40%; text-align:center;" | {| class="wikitable" style="width: 40%; text-align:center;" | ||
Line 95: | Line 90: | ||
|- | |- | ||
|} | |} | ||
− | + | <div class="toccolours" style="background-color:#b3e2cd"> | |
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Busulfan (Myleran)]] | *[[Busulfan (Myleran)]] | ||
+ | </div></div> | ||
===References=== | ===References=== | ||
# Schilling RF, Meyer OO. Treatment of chronic granulocytic leukemia with 1, 4-dimethanesulfonyloxybutane (Myleran). N Engl J Med. 1956 May 24;254(21):986-9. [https://doi.org/10.1056/NEJM195605242542104 link to original article] [https://pubmed.ncbi.nlm.nih.gov/13322198 PubMed] | # Schilling RF, Meyer OO. Treatment of chronic granulocytic leukemia with 1, 4-dimethanesulfonyloxybutane (Myleran). N Engl J Med. 1956 May 24;254(21):986-9. [https://doi.org/10.1056/NEJM195605242542104 link to original article] [https://pubmed.ncbi.nlm.nih.gov/13322198 PubMed] | ||
# Unugur A, Schulman E, Dameshek W. Treatment of chronic granulocytic leukemia with Myleran. N Engl J Med. 1957 Apr 18;256(16):727-34. [https://doi.org/10.1056/NEJM195704182561602 link to original article] [https://pubmed.ncbi.nlm.nih.gov/13451927 PubMed] | # Unugur A, Schulman E, Dameshek W. Treatment of chronic granulocytic leukemia with Myleran. N Engl J Med. 1957 Apr 18;256(16):727-34. [https://doi.org/10.1056/NEJM195704182561602 link to original article] [https://pubmed.ncbi.nlm.nih.gov/13451927 PubMed] | ||
− | |||
==Interferon alfa-2b & DLI {{#subobject:5e6fed|Regimen=1}}== | ==Interferon alfa-2b & DLI {{#subobject:5e6fed|Regimen=1}}== | ||
− | |||
DLI: '''<u>D</u>'''onor '''<u>L</u>'''ymphocyte '''<u>I</u>'''nfusion | DLI: '''<u>D</u>'''onor '''<u>L</u>'''ymphocyte '''<u>I</u>'''nfusion | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
===Regimen {{#subobject:26844e|Variant=1}}=== | ===Regimen {{#subobject:26844e|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 60%; text-align:center;" | {| class="wikitable sortable" style="width: 60%; text-align:center;" | ||
Line 116: | Line 111: | ||
|- | |- | ||
|} | |} | ||
− | ''Patients had relapsed after allogeneic HSCT'' | + | ''Note: Patients had relapsed after allogeneic HSCT'' |
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Immunotherapy==== | ====Immunotherapy==== | ||
*[[Interferon alfa-2b (Intron-A)]] | *[[Interferon alfa-2b (Intron-A)]] | ||
*DLI | *DLI | ||
+ | </div></div> | ||
===References=== | ===References=== | ||
# Porter DL, Roth MS, McGarigle C, Ferrara JL, Antin JH. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med. 1994 Jan 13;330(2):100-6. [https://doi.org/10.1056/NEJM199401133300204 link to original article] [https://pubmed.ncbi.nlm.nih.gov/8259165 PubMed] | # Porter DL, Roth MS, McGarigle C, Ferrara JL, Antin JH. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med. 1994 Jan 13;330(2):100-6. [https://doi.org/10.1056/NEJM199401133300204 link to original article] [https://pubmed.ncbi.nlm.nih.gov/8259165 PubMed] | ||
− | |||
=Blast crisis= | =Blast crisis= | ||
==Hydroxyurea & Plicamycin {{#subobject:7d26h7|Regimen=1}}== | ==Hydroxyurea & Plicamycin {{#subobject:7d26h7|Regimen=1}}== | ||
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
− | |||
===Regimen {{#subobject:af8acb|Variant=1}}=== | ===Regimen {{#subobject:af8acb|Variant=1}}=== | ||
{| class="wikitable" style="width: 60%; text-align:center;" | {| class="wikitable" style="width: 60%; text-align:center;" | ||
Line 138: | Line 133: | ||
|- | |- | ||
|} | |} | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Hydroxyurea (Hydrea)]] | *[[Hydroxyurea (Hydrea)]] | ||
*[[Plicamycin (Mithracin)]] | *[[Plicamycin (Mithracin)]] | ||
− | + | </div></div> | |
===References=== | ===References=== | ||
# Koller CA, Miller DM. Preliminary observations on the therapy of the myeloid blast phase of chronic granulocytic leukemia with plicamycin and hydroxyurea. N Engl J Med. 1986 Dec 4;315(23):1433-8. [https://doi.org/10.1056/NEJM198612043152301 link to original article] [https://pubmed.ncbi.nlm.nih.gov/2431313 PubMed] | # Koller CA, Miller DM. Preliminary observations on the therapy of the myeloid blast phase of chronic granulocytic leukemia with plicamycin and hydroxyurea. N Engl J Med. 1986 Dec 4;315(23):1433-8. [https://doi.org/10.1056/NEJM198612043152301 link to original article] [https://pubmed.ncbi.nlm.nih.gov/2431313 PubMed] | ||
− | |||
==Vincristine & Prednisone {{#subobject:7d31e7|Regimen=1}}== | ==Vincristine & Prednisone {{#subobject:7d31e7|Regimen=1}}== | ||
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
− | |||
===Regimen {{#subobject:af8942|Variant=1}}=== | ===Regimen {{#subobject:af8942|Variant=1}}=== | ||
{| class="wikitable" style="width: 40%; text-align:center;" | {| class="wikitable" style="width: 40%; text-align:center;" | ||
Line 157: | Line 151: | ||
|- | |- | ||
|} | |} | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Vincristine (Oncovin)]] | *[[Vincristine (Oncovin)]] | ||
====Glucocorticoid therapy==== | ====Glucocorticoid therapy==== | ||
*[[Prednisone (Sterapred)]] | *[[Prednisone (Sterapred)]] | ||
+ | </div></div> | ||
===References=== | ===References=== | ||
# Marks SM, Baltimore D, McCaffrey R. Terminal transferase as a predictor of initial responsiveness to vincristine and prednisone in blastic chronic myelogenous leukemia: a co-operative study. N Engl J Med. 1978 Apr 13;298(15):812-4. [https://doi.org/10.1056/NEJM197804132981503 link to original article] [https://pubmed.ncbi.nlm.nih.gov/273142 PubMed] | # Marks SM, Baltimore D, McCaffrey R. Terminal transferase as a predictor of initial responsiveness to vincristine and prednisone in blastic chronic myelogenous leukemia: a co-operative study. N Engl J Med. 1978 Apr 13;298(15):812-4. [https://doi.org/10.1056/NEJM197804132981503 link to original article] [https://pubmed.ncbi.nlm.nih.gov/273142 PubMed] | ||
− | |||
[[Category:Chronic myeloid leukemia regimens]] | [[Category:Chronic myeloid leukemia regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
[[Category:Myeloproliferative neoplasms]] | [[Category:Myeloproliferative neoplasms]] | ||
[[Category:Historical regimens]] | [[Category:Historical regimens]] |
Revision as of 14:21, 24 February 2023
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the NCCN Guidelines. Is there a regimen missing from this list? See the main CML page for current regimens.
8 regimens on this page
8 variants on this page
|
Chronic phase, first-line therapy
Hydroxyurea & Interferon alfa-2a
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Hehlmann et al. 2003 (CML-Study II) | 1991-1994 | Phase 3 (E-esc) | Hydroxyurea | Superior OS |
Hehlmann et al. 2007 (CML-Study III) | 1995-2001 | Phase 3 (E-de-esc) | Allo HSCT (no specific conditioning regimen) | Seems to have superior OS |
Gratwohl et al. 2015 (CML-Study IIIA) | 1997-2004 | Phase 3 (C) | Allo HSCT (no specific conditioning regimen) | Did not meet primary endpoint of OS |
Note: One of the few regimens compared in large RCTs against allogeneic HSCT.
References
- CML-Study II: Hehlmann R, Berger U, Pfirrmann M, Hochhaus A, Metzgeroth G, Maywald O, Hasford J, Reiter A, Hossfeld DK, Kolb HJ, Löffler H, Pralle H, Queisser W, Griesshammer M, Nerl C, Kuse R, Tobler A, Eimermacher H, Tichelli A, Aul C, Wilhelm M, Fischer JT, Perker M, Scheid C, Schenk M, Weiss J, Meier CR, Kremers S, Labedzki L, Schmeiser T, Lohrmann HP, Heimpel H; German CML Study Group. Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea. Leukemia. 2003 Aug;17(8):1529-37. link to original article PubMed
- CML-Study III: Hehlmann R, Berger U, Pfirrmann M, Heimpel H, Hochhaus A, Hasford J, Kolb HJ, Lahaye T, Maywald O, Reiter A, Hossfeld DK, Huber C, Löffler H, Pralle H, Queisser W, Tobler A, Nerl C, Solenthaler M, Goebeler ME, Griesshammer M, Fischer T, Kremers S, Eimermacher H, Pfreundschuh M, Hirschmann WD, Lechner K, Wassmann B, Falge C, Kirchner HH, Gratwohl A. Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood. 2007 Jun 1;109(11):4686-92. Epub 2007 Feb 22. link to original article does not contain dosing details PubMed NCT00002771
- CML-Study IIIA: Gratwohl A, Pfirrmann M, Zander A, Kröger N, Beelen D, Novotny J, Nerl C, Scheid C, Spiekermann K, Mayer J, Sayer HG, Falge C, Bunjes D, Döhner H, Ganser A, Schmidt-Wolf I, Schwerdtfeger R, Baurmann H, Kuse R, Schmitz N, Wehmeier A, Fischer JT, Ho AD, Wilhelm M, Goebeler ME, Lindemann HW, Bormann M, Hertenstein B, Schlimok G, Baerlocher GM, Aul C, Pfreundschuh M, Fabian M, Staib P, Edinger M, Schatz M, Fauser A, Arnold R, Kindler T, Wulf G, Rosselet A, Hellmann A, Schäfer E, Prümmer O, Schenk M, Hasford J, Heimpel H, Hossfeld DK, Kolb HJ, Büsche G, Haferlach C, Schnittger S, Müller MC, Reiter A, Berger U, Saußele S, Hochhaus A, Hehlmann R; SAKK; German CML Study Group. Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment. Leukemia. 2016 Mar;30(3):562-9. Epub 2015 Oct 14. link to original article does not contain dosing details link to PMC article PubMed NCT00025402
Interferon alfa monotherapy
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Hehlmann et al. 1994 | 1983-1991 | Phase 3 (E-switch-ooc) | 1. Busulfan | Superior OS |
2. Hydrea | Did not meet primary endpoint of OS |
Note: This article does not specify the exact type of interferon alfa.
References
- Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, Queisser W, Löffler H, Hochhaus A, Heinze B, Georgii A, Bartram CR, Griesshammer M, Bergmann L, Essers U, Falge C, Queisser U, Meyer P, Schmitz N, Eimermacher H, Walther F, Fett W, Kleeberg UR, Kabisch A, Nerl C, Zimmermann R, Meuret G, Tichelli A, Kanz L, Tigges FJ, Schmid L, Brockhaus W, Tobler A, Reiter A, Perker M, Emmerich B, Verpoort K, Zankovich R, Wussow PV, Prummer O, Thiele J, Buhr T, Carbonell F, Ansari H; German CML Study Group. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood. 1994 Dec 15;84(12):4064-77. link to original article PubMed
Chronic phase, relapsed or refractory
Busulfan monotherapy
Regimen
Study | Evidence |
---|---|
Schilling & Meyer 1956 | Non-randomized, <20 pts |
Unugur et al. 1957 | Non-randomized |
Chemotherapy
References
- Schilling RF, Meyer OO. Treatment of chronic granulocytic leukemia with 1, 4-dimethanesulfonyloxybutane (Myleran). N Engl J Med. 1956 May 24;254(21):986-9. link to original article PubMed
- Unugur A, Schulman E, Dameshek W. Treatment of chronic granulocytic leukemia with Myleran. N Engl J Med. 1957 Apr 18;256(16):727-34. link to original article PubMed
Interferon alfa-2b & DLI
DLI: Donor Lymphocyte Infusion
Regimen
Study | Years of enrollment | Evidence |
---|---|---|
Porter et al. 1994 | NR | Non-randomized, <20 pts |
Note: Patients had relapsed after allogeneic HSCT
Immunotherapy
References
- Porter DL, Roth MS, McGarigle C, Ferrara JL, Antin JH. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med. 1994 Jan 13;330(2):100-6. link to original article PubMed
Blast crisis
Hydroxyurea & Plicamycin
References
- Koller CA, Miller DM. Preliminary observations on the therapy of the myeloid blast phase of chronic granulocytic leukemia with plicamycin and hydroxyurea. N Engl J Med. 1986 Dec 4;315(23):1433-8. link to original article PubMed
Vincristine & Prednisone
Regimen
Study | Evidence |
---|---|
Marks et al. 1978 | Non-randomized |
References
- Marks SM, Baltimore D, McCaffrey R. Terminal transferase as a predictor of initial responsiveness to vincristine and prednisone in blastic chronic myelogenous leukemia: a co-operative study. N Engl J Med. 1978 Apr 13;298(15):812-4. link to original article PubMed